Country Access Report
Lebanon maintains a conventional medical/regulatory approach: ketamine and the esketamine product Spravato are registered with the Ministry of Public Health and are available for medical use in healthcare settings, while classical serotonergic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, ayahuasca), ibogaine and 2C‑X family substances have no authorized routine medical program and are treated as controlled/illicit substances outside of regulated research or criminal enforcement. Public reimbursement for high-cost specialty psychiatric products is limited; availability is primarily via registered hospital pharmacies or private clinics and often without broad public subsidy. Lebanese Ministry of Public Health — National Drugs Database.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Evidence of Lebanese law enforcement treating novel/plant/tryptamine-type psychoactives as illicit is visible in public drug‑control operations and reporting; there is no registration or listing for psilocybin or psilocin in the Ministry of Public Health national drugs database. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Lebanese law‑enforcement reporting routinely lists MDMA/ecstasy in drug seizures and prosecutions; there is no evidence of a registered medical MDMA program or reimbursement pathway in Lebanon's Ministry of Public Health registry. [1].
Compound Access
Esketamine (Spravato) is present in the Lebanese Ministry of Public Health national drugs database as a registered pharmaceutical product (brand: SPRAVATO). The MOPH listings include multiple Spravato product entries and prices, indicating formal registration/market authorization status in Lebanon and availability through registered supply channels. This registration means esketamine may be legally imported, distributed and administered within certified medical settings in Lebanon, subject to product labelling and national regulations overseen by the Ministry of Public Health. [1].
Reimbursement and coverage: the MOPH database lists retail/price points for Spravato but does not by itself guarantee broad public subsidy; high-cost specialist psychiatric medicines in Lebanon are commonly funded either by private insurance, employer health plans, or out‑of‑pocket payment unless specifically included in a public subsidy list. Clinicians should confirm case‑by‑case with the Ministry of Public Health, hospital pharmacy procurement offices, and the patient’s insurer whether Spravato is reimbursable or requires special authorization. [1].
Compound Access
Ketamine (injectable ketamine HCl) is a registered, listed medicine in the Lebanese Ministry of Public Health national drugs database for licensed medical indications (primarily an anaesthetic/analgesic formulation) and is available through hospital pharmacies and authorised providers. The MOPH product listing shows registered ketamine injectable preparations and pricing, demonstrating legal medical availability for approved anaesthesia/analgesia uses. [1].
Off‑label psychiatric use: as in many countries, ketamine is sometimes used off‑label for treatment‑resistant depression and other psychiatric indications under physician supervision; however, ketamine is not licensed specifically as an antidepressant and off‑label psychiatric use does not automatically confer public reimbursement. In Lebanon such off‑label psychiatric applications would typically be delivered in private clinics or tertiary hospitals, billed through private insurance or self‑pay, unless a specific public subsidy or hospital programme is established. Clinicians and patients should verify coverage with private insurers and hospital financing offices, and follow Ministry of Public Health rules for controlled medicines. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no registration for DMT products in the Ministry of Public Health database and law‑enforcement activity treats traceable/synthetic tryptamines as illicit. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No evidence of registered therapeutic 5‑MeO‑DMT products exists in the MOPH registry for Lebanon. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Internationally ibogaine is often in a legal gray zone; in Lebanon there is no registered ibogaine product and no public medical programme or reimbursement pathway. Law‑enforcement reporting on controlled‑substance seizures and the absence of registration indicate it is not an authorised reimbursed treatment. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The active constituents of ayahuasca (DMT and MAO‑inhibiting plant materials) are not registered medical products in Lebanon and traditional/ceremonial use would fall outside legal medical frameworks. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no registration for mescaline or peyote‑derived medicinal products in Lebanon’s national database. [1].
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamine psychedelics of the 2C family are not registered medicines in Lebanon and are subject to criminal enforcement when encountered by authorities. Lebanese law‑enforcement public reporting of seizures confirms operational control against synthetic novel psychoactive substances. [1].
Last updated 14 May 2026. Source links come from the medical access guide.